EP4701643A1 - Extrazelluläre vesikel mit 15-lipoxygenase - Google Patents

Extrazelluläre vesikel mit 15-lipoxygenase

Info

Publication number
EP4701643A1
EP4701643A1 EP24724584.8A EP24724584A EP4701643A1 EP 4701643 A1 EP4701643 A1 EP 4701643A1 EP 24724584 A EP24724584 A EP 24724584A EP 4701643 A1 EP4701643 A1 EP 4701643A1
Authority
EP
European Patent Office
Prior art keywords
lox
acdev
lipoxygenase
cells
typically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24724584.8A
Other languages
English (en)
French (fr)
Inventor
Andrew Devitt
Ivana MILIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aston University
Original Assignee
Aston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aston University filed Critical Aston University
Publication of EP4701643A1 publication Critical patent/EP4701643A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24724584.8A 2023-04-25 2024-04-24 Extrazelluläre vesikel mit 15-lipoxygenase Pending EP4701643A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2306026.2A GB202306026D0 (en) 2023-04-25 2023-04-25 Extracellular vesicles
PCT/GB2024/051055 WO2024224058A1 (en) 2023-04-25 2024-04-24 Extracellular vesicles comprising 15-lipoxygenase

Publications (1)

Publication Number Publication Date
EP4701643A1 true EP4701643A1 (de) 2026-03-04

Family

ID=86605380

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24724584.8A Pending EP4701643A1 (de) 2023-04-25 2024-04-24 Extrazelluläre vesikel mit 15-lipoxygenase

Country Status (3)

Country Link
EP (1) EP4701643A1 (de)
GB (1) GB202306026D0 (de)
WO (1) WO2024224058A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702863D0 (en) 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2020132161A1 (en) * 2018-12-21 2020-06-25 The Regents Of The University Of California Compositions and methods for treating hearing loss
GB201906482D0 (en) 2019-05-08 2019-06-19 Evox Therapeutics Ltd Exosome comprising stabilized RNA therapeutics
GB202105925D0 (en) 2021-04-26 2021-06-09 Evox Therapeutics Ltd Modified extracellular vesicles (EVs) with improved half-life
CN114272265A (zh) * 2022-01-21 2022-04-05 上海市东方医院（同济大学附属东方医院） 来源于正常组织间隙的胞外囊泡及其用途

Also Published As

Publication number Publication date
GB202306026D0 (en) 2023-06-07
WO2024224058A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
Hyvärinen et al. Mesenchymal stromal cells and their extracellular vesicles enhance the anti-inflammatory phenotype of regulatory macrophages by downregulating the production of interleukin (IL)-23 and IL-22
Hunt et al. Acetyl-CoA carboxylase obstructs CD8+ T cell lipid utilization in the tumor microenvironment
Esser et al. Exosomes from human macrophages and dendritic cells contain enzymes for leukotriene biosynthesis and promote granulocyte migration
Rubic et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity
Yokota et al. GM-CSF and IL-4 synergistically trigger dendritic cells to acquire retinoic acid-producing capacity
Suzuki et al. The tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting mTORC1-dependent metabolic activation
Shen et al. HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells
Rothe et al. 12/15-lipoxygenase–mediated enzymatic lipid oxidation regulates DC maturation and function
Feng et al. Generation of mucosal dendritic cells from bone marrow reveals a critical role of retinoic acid
Caslin et al. Inhibiting glycolysis and ATP production attenuates IL-33-mediated mast cell function and peritonitis
Lepore et al. A novel self-lipid antigen targets human T cells against CD1c+ leukemias
Facciotti et al. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus
Dong et al. CD44 loss disrupts lung lipid surfactant homeostasis and exacerbates oxidized lipid-induced lung inflammation
Kemp et al. Fatty acid oxidation in immune function
Oner et al. Resolvin E1 regulates Th17 function and T cell activation
Singh et al. 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells
Kim et al. Natural killer cells regulate eosinophilic inflammation in chronic rhinosinusitis
Sousa et al. Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells
Kobayashi et al. Dietary supplementation with eicosapentaenoic acid inhibits plasma cell differentiation and attenuates lupus autoimmunity
Hirata et al. Maternal ω3 docosapentaenoic acid inhibits infant allergic dermatitis through TRAIL‐expressing plasmacytoid dendritic cells in mice
Kollareth et al. Lipoxin A4/FPR2 signaling mitigates ferroptosis of alveolar epithelial cells via NRF2-dependent pathway during lung ischemia-reperfusion injury
Toki et al. PGI2 signaling inhibits antigen uptake and increases migration of immature dendritic cells
WO2011060329A1 (en) Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
Watson et al. mTORC2 deficiency alters the metabolic profile of conventional dendritic cells
Zhu et al. SLC38A5 aggravates DC-mediated psoriasiform skin inflammation via potentiating lysosomal acidification

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR